New drug combo shows promise for rare salivary gland cancers

NCT ID NCT04209660

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, lenvatinib and pembrolizumab, can shrink or slow the growth of advanced salivary gland cancers, including adenoid cystic carcinoma, that have come back or spread. About 64 participants will receive the combination therapy. The goal is to see how well the drugs work and to check for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma salivary gland cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA SALIVARY GLAND CANCER

Contacts and locations

Locations

Baptist Alliance MCI

Miami, Florida, 33143, United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (All Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.